iiinova — where your digital self keeps evolving

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 26/09/2026

#ASTRO26 is officially in session, in Boston! Excited to learn about new advancements, updates in #radonc and for connection & collaboration

000

Reposted by Chaewon Hwang, M.D.

American Society of Clinical Oncology @ascocancer.bsky.social · 14/09/2026

Upcoming Medicaid work requirements starting in 2027 could impact coverage and care delivery for patients with cancer. We break down what these policy changes mean and how we are working to protect patient access to care. Learn more: bit.ly/4rcyCA4 #ASCOAdvocacy

001

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 04/06/2026

Deeply honored to receive the #GRASPAdvocateChoiceAward, for our work presented at #ASCO26, www.asco.org/abstracts-pr.... Grateful for my collaborators, especially Jason Jincong Freeman, PhD, and mentor Kathryn Huber, MD PhD. I am excited to share this work with patient advocates 6/11/26!

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 01/06/2026

Incredible finding for treatment of previously treated metastatic pancreatic cancer using targeted therapy. Exciting to see more and more targeted agents emerge that we can use to help treat patients #ASCO26

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 30/05/2026

#RealWorldData on OS differences for px with Stage III #NSCLC s/p #ChemoRT, eligible for #immunotherapy 2018-2020. Treatment facility & insurance = independent predictors of OS. ~54% received IO. IO receipt was associated with 47% mortality risk reduction. #ASCO26 @bidmc-cancercenter.bsky.social

020

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 29/05/2026

Excited to share our #RealWorldData and evidence on socioeconomic and clinical factors associated with OS in patients with Stage III #NSCLC following #chemoRT in the post-PACIFIC era! Stop by, 9am-12pm, 5/30! #ASCO2026 #LungCancer @ascocancer.bsky.social @bidmc-cancercenter.bsky.social @TuftsMedCtr

020

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 29/05/2026

Thrilled to be back at @ascocancer.bsky.social annual meeting for #ASCO2026 ! Honored to be a part of this inspiring global oncology community with common goal of conquering cancer

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 23/03/2026

We are thrilled to welcome Rita & Danny to our Residency Program @TuftsMCRadOnc, allied with @BIDMC and @UMass!🎉 #Match2026 #RadOnc #ResidencyMatch

010

Reposted by Chaewon Hwang, M.D.

The ASCO Post @ascopost.bsky.social · 16/10/2025

FANSS study: low-dose CT screening feasible, valuable for lung cancer screening for Asian non-smoking women Supports expansion of guidelines to include high-risk populations Presenter: @elaineshummd.bsky.social Discussant: David R. Baldwin, MD ascopost.com/news/october...

022

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 12/10/2025

Additionally, there was no correlation between level of #financialtoxicity and the type of planned #radiationtherapy, CyberKnife SBRT, or hypofractionated/conventional EBRT. Important to note that this was baseline survey prior to start of RT! Longitudinal data is being collected

000

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 12/10/2025

Despite our prostate cancer patients being more likely to report low #financialtoxicity, those with high FT were still more likely to engage in cost-coping mechanisms like delaying or avoiding medical care and reducing spending on leisure, which can negatively impact outcomes and QoL

120

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 07/10/2025

Excited to share our findings regarding #financialtoxicity of our patients with prostate cancer presenting for #radiationtherapy @bidmc-cancercenter.bsky.social @bidmcreseach.bsky.social ! And excited to learn more about delivery of quality care and barriers to cancer care at #ASCOQLTY25!

111

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 29/09/2025

#ASTRO25 ! Thank you for the opportunity to present our work on #financialtoxicity in patients undergoing radiation treatment, specifically on baseline FT and cost-coping mechanisms. Stay tuned for #ASCOQLTY25 for subanalysis on our prostate cancer patient cohort! #radonc

000

Reposted by Chaewon Hwang, M.D.

American Society of Clinical Oncology @ascocancer.bsky.social · 02/09/2025

Abstract titles for #ASCOQLTY25 are now live! Get a first look at the solution-oriented cancer research that will be presented at the symposium: asco.org/qcs-abstracts If you haven’t yet confirmed your attendance, registration is still open: brnw.ch/21wVpzR

044

Reposted by Chaewon Hwang, M.D.

American Society of Clinical Oncology @ascocancer.bsky.social · 01/06/2025

More news from #ASCO25 Plenary! MATTERHORN results: Perioperative durvalumab/FLOT shows superior EFS over placebo/FLOT in early-stage, resectable G/GEJ cancer: brnw.ch/21wT4R8 #ASCODailyNews #GICSM

033

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 01/06/2025

Day 3 of #ASCO25 ! Honored to be presenting on how social determinants of health affect immunotherapy use in Stage III NSCLC patients after definitive chemoradiation @ascocancer.bsky.social @bidmcreseach.bsky.social @bidmc-cancercenter.bsky.social #TuftsMedicalCenter

020

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 31/05/2025

Day 2 of #ASCO25! Exciting new frontiers in harnessing power of AI to better cancer care! As Dr. Robin Zon, President of @ascocancer.bsky.social, & Ms. Ruth Porat, President & CIO of Google and Alphabet, mentioned, AI is augmenting human capabilities, and it's about using it as an agent for change

010

Reposted by Chaewon Hwang, M.D.

American Society of Clinical Oncology @ascocancer.bsky.social · 31/05/2025

@cliffordhudis.bsky.social at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever ➡️ brnw.ch/21wT3U4

brnw.ch

Federal Funding for Cancer Research

As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.

02514

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 30/05/2025

Thrilled to be at #ASCO25 ! Excited to witness and be a part of the forefront of cancer research! And honored to present research @ascocancer.bsky.social

020

Reposted by Chaewon Hwang, M.D.

American Society of Clinical Oncology @ascocancer.bsky.social · 22/05/2025

The most clinically relevant science in oncology will be presented at #ASCO25, and you can now view the full 5,000 abstracts & their presentation date, time & location info: brnw.ch/21wSRrH

01610

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 29/04/2025

Incredible findings of Phase II study where px with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoaduvant dostarlimab for 6 months: ➡️ recurrence-free survival at 2 years was 92% #AACR25 #Oncology #research www.nejm.org/doi/full/10....

nejm.org

Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM

Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 28/04/2025

📣 Phase III KEYNOTE-689 trial: Addition of perioperative Pembrolizumab to standard of care tx for locally advanced HNSCC significantly improved event free survival and major pathologic response. Presented @ #AACR 2025 meeting: www.aacr.org/about-the-aa... #Oncology #research #radonc

aacr.org

About the AACR

The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer.

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 27/04/2025

Helpful guide to responding to reviewers, when submitting research to journals: www.sciencedirect.com/science/arti... #meded #oncology #research #radonc

sciencedirect.com

How To Write a Response to Reviewers

010

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 23/04/2025

Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT: meetings.asco.org/abstracts-pr... @bidmcreseach.bsky.social #TuftsMedicine

meetings.asco.org

Program Guide – ASCO Meeting Program Guide

000

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 10/04/2025

📣 Big shoutout to our faculty at #TuftsMedicine & @bidmc-cancercenter.bsky.social radiation oncology residency, Dr. Jang and Dr. Huber, for being speaker and moderator at this year's @astro-org.bsky.social Annual RefresherCourse! Thank you for all that you do for us and for the #radonc community!

000

Chaewon Hwang, M.D. @chaewonhwangmd.bsky.social · 02/04/2025

"Deintensification of chemoradiation treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches should remain experimental.” — SUE YOM, MD, PhD, FASTRO. ascopost.com/news/april-2... @ascopost.bsky.social

ascopost.com

Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer

Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 ...

000

Reposted by Chaewon Hwang, M.D.

American College of Radiation Oncology @acroradonc.bsky.social · 21/03/2025

We had a record number of abstracts submitted for #ACRO2025! 👏 Impressive work by all our residents who presented at #ACROinVegas! See all the photos here: www.facebook.com/media/set?va...

021